Answers are grounded in this paper and cite their sources.
Patients with glioblastoma containing a methylated MGMT promoter benefited from temozolomide, whereas those who did not have a methylated MGMT promoter did not have such a benefit.
No takes yet. Share an insight, caveat, or question.
Hegi et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: